Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca PLC $AZN Holdings Boosted by ABC Arbitrage SA
03:32am, Wednesday, 11'th Feb 2026
ABC Arbitrage SA grew its holdings in AstraZeneca PLC (NASDAQ: AZN) by 210.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The instit
Major stock indexes were mixed Tuesday, with the Dow Jones Industrial Average setting a fresh all-time high for a third consecutive session. Meanwhile, Treasury yields ticked lower after delayed U.S.
AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy
03:43pm, Tuesday, 10'th Feb 2026
AstraZeneca PLC delivered robust 2025 results, with 9% product sales growth and a 23.4% operating margin, and raised its dividend. AZN targets $80bn in revenues by 2030, driven by oncology, pipeline l
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
12:44pm, Tuesday, 10'th Feb 2026
AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript
AZN Q4 Earnings Miss Estimates, Stock Up on Robust 2026 Growth Outlook
10:45am, Tuesday, 10'th Feb 2026
AZN misses Q4 EPS and sales estimates, but rallies after projecting mid-to-high single-digit revenue growth and low double-digit EPS growth for 2026.
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q4 Earnings
10:30am, Tuesday, 10'th Feb 2026
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street es
AstraZeneca Leans On Its Cancer Division For A Fourth-Quarter Beat
09:09am, Tuesday, 10'th Feb 2026
AstraZeneca stock rose moderately Tuesday morning on better-than-expected sales and profit in the fourth quarter.
Cavendish backs 88 Energy after Namibia exploration success
07:35am, Tuesday, 10'th Feb 2026
Cavendish Securities reiterated its 'buy' rating and 21.8p target price for 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ), highlighting the...
AstraZeneca results: FY and Q4 2025
07:00am, Tuesday, 10'th Feb 2026
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary FY 2025 % Change Q4 2025 % Change $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue
AstraZeneca's growth engine stays on track despite cost pressures
06:49am, Tuesday, 10'th Feb 2026
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) full-year results showed the pharmaceutical group navigating a challenging comparison period with a robust operational performance and a renewed commitment to
AstraZeneca’s growth engine stays on track despite cost pressures
06:31am, Tuesday, 10'th Feb 2026
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) full-year results showed the pharmaceutical group navigating a challenging comparison period with a robust...
AstraZeneca lifts earnings as pipeline delivery and global expansion underpin growth
03:11am, Tuesday, 10'th Feb 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) delivered strong full-year results for 2025, driven by solid commercial performance across all major regions and sustained pipeline momentum, as the Anglo-Swedish
AFC Energy signs ammonia engine deal with Komatsu
02:45am, Tuesday, 10'th Feb 2026
AFC Energy PLC (AIM:AFC, OTC:AFGYF, FRA:QC8), the AIM-listed hydrogen energy group, has signed a joint development agreement with Komatsu and its affiliate...
AstraZeneca Forecasts Continued Growth on Pipeline Strength
02:34am, Tuesday, 10'th Feb 2026
It anticipates 2026 revenue to grow by a mid-to-high single-digit percentage, and core earnings per share to climb by a low double-digit percentage.
AstraZeneca profit climbs on cancer and heart drug demand
02:24am, Tuesday, 10'th Feb 2026
The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.
